Exhibit 10.7

 

ASSIGNMENT AGREEMENT

 

This Assignment Agreement (the “Agreement”) is made as of March 15, 2016 (the “Effective Date”), by and between Tallikut Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (“Tallikut”), and Accelerated Pharma, Inc., a corporation organized under the laws of Delaware (“API”).

 

RECITALS

 

WHEREAS, Tallikut owns the right, title and interest in and to all assets related to picoplatin including licensed rights to the AnorMED patents (the “Picoplatin Assets”); and

 

WHEREAS API is desirous of acquiring the entire right, title and interest in the same.

 

NOW, THEREFORE, in consideration of the above recitals and the mutual covenants hereinafter set forth, API and Tallikut, intending to be legally bound, hereby agree as follows:

 

1.

Assignment. Tallikut agrees to sell, assign, transfer and convey to API all of Tallikut’s right, title and interest in and to all of the following (collectively, the “Property Rights”):

 

1.1. the worldwide rights, title and interest in and to any and all trade names, trademark rights, trademarks and service marks (including any and all registrations, licenses, applications and common law marks pertaining thereto), used in connection with the Picoplatin Assets, together with (a) the goodwill of the Picoplatin Assets associated therewith and symbolized by same and (b) all common law rights therein and the right to sue for past infringement of any and all of said trademarks (collectively, the “Trademarks”);

 

1.2. all worldwide rights, title and interest of Tallikut in and to the designs, processes, drawings, schematics, copyrights and copyright applications, if any, inventions, processes, know-how, trade secrets, patents (including any and all letter patents) patent applications (including any Patent Cooperation Treaty patent applications and corresponding National patent applications) and other proprietary information related to the Picoplatin Assets, including, without limitation, any registered copyrights, patents and copyright and patent applications identified on Exhibit E, and in and to all substitutions, divisions, continuations, continuationsin-part, reexaminations, extensions, renewals and reissues (as applicable) thereof, and including without limitation of generality, all rights of priority resulting from the filing of patent applications relating to any of the foregoing as well as any and all choses in action and any and all claims and demands, both at law and in equity, that Tallikut has or may have for damages or profits accrued or to accrue on account of the infringement of any patents, patent applications, letter patents, inventions, improvements and discoveries (or any provisional rights therein), the same to be held and enjoyed by API, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by Tallikut if the assignment set forth herein had not occurred, the full and complete right to file patent applications on the aforesaid inventions, improvements, discoveries and applications in all countries of the world and the entire right, title and interest in and to any letter patent which may issue thereon in the United States or in any country, and any and all renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same (collectively, the “Intellectual Property Rights”);

 

 

1.3. all files, lists, publications, and other records and data of Tallikut used in or relating to the Picoplatin Assets, regardless of the medium on which such information is stored and maintained; and

 

1.4. all rights in and to any governmental and private permits, licenses, and authorizations, to the extent assignable, used in or relating to the Picoplatin Assets.

 

2.    Title Passage. Upon the Effective Date, title to all of the Property Rights shall pass to API. Tallikut shall, upon API’s request, execute any assignments, conveyances and/or bills of sale required to assign, transfer, set over, convey, assure and confirm unto and vest in API, its successors and assigns, title to all of the Property Rights, as well as such other instruments of conveyance as counsel for API may reasonably deem necessary to effect or evidence the transfers contemplated hereby.

 

3.    Purchase Price. The aggregate consideration for the sale, transfer, conveyance and assignment of all the Property Rights to API shall be $1 (the “Purchase Price”), receipt of which is hereby acknowledged.

 

 

IN WITNESS WHEREOF, the parties hereto have duly executed this Assignment Agreement on the dates indicated below.

 

TALLIKUT PHARMACEUTICALS, INC.			ACCELERATED PHARMA, INC.
By	/s/ Fred Craves		By:	/s/ Michael Fonstein
Name:	Fred Craves		Name:	Michael Fonstein
Title:	Chairman of the Board		Title:	Chief Executive Officer
Date:	3/15/16		Date:	3/15/16

 

State of _________________________________

County of________________________________

 

ACKNOWLEDGMENT

 

On this________ day of March, in the year 2016, before me, the undersigned, personally appeared Fred Craves, the Chairman of the Board of Tallikut Pharmaceuticals, Inc., a corporation organized under the laws of Delaware, personally known to me or proved to me on the basis of satisfactory evidence to be the person who executed the within Assignment Agreement in his or her capacity behalf of said corporation and acknowledged to me that he or she executed the same for the purposes therein stated.

 

Seal:

 

Notary Public____________________________

My commission expires:

 

[SIGNATURE PAGE TO ASSIGNMENT AGREEMENT]

 

 

CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

 

State of California
County of   San Francisco

 

On	3/15/16	before me,	M. A. Josephson
	Date		Here Insert Name and Title of the Officer

 

Personally appeared	/s/ Fred Craves
	Name(s) of Signer(s)

 

	who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.
	I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.
	WITNESS my hand and official seal.
	Signature	/s/ M. A. Josephson
Place Notary Seal above		Signature of Notary Public

 

OPTIONAL

 

Though the information below is not required by law, it may prove valuable to persons relying on the document
and could prevent fraudulent removal and reattachment of this form to another document.

 

Description of Attached Document

 

Title or Type of Document:

 

Document Date:

Number of Pages:

 

Signer(s) Other Than Named Above:

 

Capacity(ies) Claimed by Signer(s

 

Signer’s Name: ______________________			Signer’s Name: _________________________
¨ Individual			¨ Individual
¨ Corporate Officer — Title(s): ________			¨ Corporate Officer — Title(s): ____________
¨ Partner — ¨ Limited ¨ General			¨ Partner — ¨ Limited ¨ General

¨ Attorney in Fact			¨ Attorney in Fact
¨ Trustee			¨ Trustee
¨ Guardian or Conservator			¨ Guardian or Conservator
¨ Other: _______________________			¨ Other: ____________________
_______________________________			____________________________
Signer Is Representing: ____________			Signer Is Representing: _________
______________________________			____________________________
______________________________			____________________________

 

 

©2007 National Notary Association• 9350 De Solo Ave., P.O. Box 2402 *Chatsworth. CA 91313.2402 • www NationalNotary.org Item #5907 Reorder:Call Toll-Free 1-800-876-6827

 

 

EXHIBIT E

 

Intellectual Property Rights

 

				Application No. or Registration No.		Application Filing Date or Registration
Patent		Country		as applicable)		Date (as applicable)
USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER		US		60/857,067		11/6/2006
USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER		US		60/877,515		12/28/2006
USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER		US		60/927,347		5/3/2007
USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER		US		60/931,309		5/22/2007
USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER		US		60/969,441		8/31/2007
USE OF PICOPLATTN TO TREAT SMALL CELL LUNG CANCER		US		12/508,392		7/23/2009
A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER		US		60/857,017		11/6/2006
A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER		US		60/857,564		11/8/2006
A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER		US		60/877,570		12/28/2006
USE OF PICOPLATTN TO TREAT PROSTATE CANCER		US		60/889,179		2/9/2007

 

 

				Application No.
				or Registration		Application Filing
				No.		Date or Registration
Patent		Country		(as applicable)		Date (as applicable)
USE OF PICOPLATIN TO TREAT PROSTATE CANCER		US		60/890,950		2/21/2007
USE OF PICOPLATIN TO TREAT PROSTATE CANCER		US		60/931,609		5/24/2007
USE OF PICOPLATIN TO TREAT PROSTATE CANCER		US		60/952,440		7/27/2007
USE OF PICOPLATIN TO TREAT PROSTATE CANCER		US		11/935,979		11/6/2007
A METHOD OF TREATMENT OF COLORECTAL CANCER		US		60/857,066		11/6/2006
A METHOD OF TREATMENT OF COLORECTAL CANCER		US		60/857/725		11/8/2006
A METHOD OF TREATMENT OF COLORECTAL CANCER		US		60/877,495		12/28/2006
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER		US		60/889,191		2/9/2007
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER		US		60/931,589		5/24/2007
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER		US		60/683,852		10/30/2007
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER		US		12/367,394		2/6/2009

 

 

				Application No.
				or Registration		Application Filing
				No.		Date or Registration
Patent		Country		(as applicable)		Date (as applicable)
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER		US		121464,662		5/12/2009
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER		US		121465,563		5/13/2009
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER		US		12/508,372		7/23/2009
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER		PCT		PCT/U52010/34593		5/12/2010
USE OF PICOPLATIN TO TREAT COLORECTAL CANCER		US		13/319,852		11/10/2011
ENCAPSULATED PICOPLATIN		US		60/889,201		2/912007
ENCAPSULATED PICOPLATIN		US		60/889,675		2/13/2007
ENCAPSULATED PICOPLAT1N		US		60/984,156		10/31/2007
ENCAPSULATED PICOPLATIN		US		60/989,020		11/19/2007
ENCAPSULATED PICOPLATIN		PCT		PCT/U52008/00174 6		2/8/2009
ENCAPSULATED PICOPLATIN		US		12/536,311		8/5/2009

 

 

				Application No. or Registration No.		Application Filing Date or Registration
Patent		Country		(as applicable)		Date (as applicable)
ENCAPSULATED PICOPLATIN		AU		2008214199		2/8/2008
ENCAPSULATED PICOPLATIN		BR		PI 0806362-1		2/8/2008
ENCAPSULATED PICOPLATIN		CA		2,677,639		2/8/2008
ENCAPSULATED PICOPLATIN		CN		200880011347.9		2/8/2008
ENCAPSULATED PICOPLAHN		EG		1200/2009		2/8/2008
ENCAPSULATED PICOPLAHN		EP		08725387.8		2/8/2008
ENCAPSULATED PICOPLATIN				10102719.4		2/8/2008
ENCAPSULATED PICOPLATIN		ID		W-00200902208		2/8/2008
ENCAPSULATED PICOPLATIN		IL		200261		2/8/2008
ENCAPSULATED PICOPLATIN		N		5257/CHENP/2009		2/8/2008
ENCAPSULATED PICOPLATIN		JP		2009-549126		2/8/2008
ENCAPSULATED PICOPLATIN		KR		10-2009-7018781		2/8/2008
ENCAPSULATED PICOPLATIN		MX		MX/s/2009/008487		2/8/2008
ENCAPSULATED PICOPLATIN		PH		1-2009-501520		2/8/2008
ENCAPSULATED PICOPLATIN		RU		2009133447		2/8/2008
ENCAPSULATED PICOPLATIN		UA		200909261		2/8/2008

 

 

				Application No.
				or Registration		Application Filing
				No.		Date or Registration
Patent		Country		(as applicable)		Date (as applicable)
ENCAPSULATED PICOPLATIN		VN		1-2009-01904		2/8/2008
STABILIZED PICOPLATIN ORAL DOSAGE FORMS		US		60/889,171		2/9/2007
STABILIZED PICOPLATIN ORAL DOSAGE FORM*		US		60/889,681		2/13/2007
STABILIZED PICOPLATIN ORAL DOSAGE FORM*		PCT		PCT/US2008/00175 2		2/8/2008
STABILIZED PICOPLATIN ORAL DOSAGE FORM*		US		12/536,335		8/5/2009
STABILIZED PICOPLATIN ORAL DOSAGE FORM*		AU		2008214202		2/8/2008
STABILIZED PICOPLATIN ORAL DOSAGE FORM*		BR		0806418-0		2/8/2008
STABILIZED PICOPLATIN ORAL DOSAGE FORM*		CA		2,677,640		2/8/2008
STABILIZED PICOPLATIN ORAL DOSAGE FORM*		CN		200880011357.2		2/8/2008
STABILIZED PICOPLATIN ORAL DOSAGE FORM*		EG		1201/2009		2/8/2008
STABILIZED PICOPLATIN ORAL DOSAGE FORM*		EP		08725393.6		2/8/2008

 

 

				Application No.
				or Registration		Application Filing
				No.		Date or Registration
Patent		Country		(as applicable)		Date (as applicable)
STABILIZED PICOPLATIN ORAL DOSAGE FORM*		HK		10106157.4		2/8/2008
STABILIZED PICOPLATIN ORAL DOSAGE FORM*		ID		W-00200902207		2/8/2008
STABILIZED PICOPLATIN ORAL DOSAGE FORM*		IL		200262		2/8/2008
STABILIZED PICOPLATIN ORAL DOSAGE FORM*		IN		5256/CHENP/2009		2/8/2008
STABILIZED PICOPLAT1N ORAL DOSAGE FORM*		JP		2009-549128		2/8/2008
STABILIZED PICOPLAT1N ORAL DOSAGE FORM*		KR		10-2009-7018780		2/8/208
STABILIZED PICOPLATIN ORAL DOSAGE FORM*		MX		MX/a/2009/008488		2/8/2008
STABILIZED PICOPLATIN ORAL DOSAGE FORM*		PH		1-2009-501521		2/8/2008
STABILIZED PICOPLATIN ORAL DOSAGE FORM*		RU		2009133446		2/8/2008
STABILIZED PICOPLATIN ORAL DOSAGE FORM*		UA		200909262		2/8/2008
STABILIZED PICOPLAT1N ORAL DOSAGE FORM AND		VN		1-2009-01903		2/8/2008

 

 

Patent		Country		Application No. or Registration No. (as applicable)		Application Filing Date or Registration Date (as applicable)
PROCESS FOR  PREPARING THE  SAME*
STABILIZED INTRAVENOUS DOSAGE FORM		US		60/949,639		6/27/2007
ORAL FORMULATION FOR PICOPLATIN		US		60/950,033		7/16/2007
ORAL FORMULATION FOR PICOPLAT1N		US		61/043,962		4/10/2008
ORAL FORMULATION FOR PICOPLATIN		PCT		PCT/U S2008/008669		7/16/2008
ORAL FORMULATION FOR PICOPLATIN		US		12/669,274		1/15/2010
ORAL FORMULATION FOR PICOPLAT1N		CA		2,693,057		7/16/2008
ORAL FORMULATION FOR PICOPLAT1N		CN		200880103323.6		7/16/2008
ORAL FORMULATION FOR PICOPLATIN		EP		08780206.2		7/16/2008
ORAL FORMULATION FOR PICOPLATIN		I-1K		11101572.1		7/16/2008
ORAL FORMULATION FOR PICOPLATIN		.1P		2010-517010		7/16/2008
ORAL FORMULATION FOR PICOPLATIN		TW		097127053		7/16/2008
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER		US		61/027,387		2/8/2008

 

 

Patent		Country		Application No. or Registration No. (as applicable)		Application Filing Date or Registration Date (as applicable)
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER		PCT		PCT/U52009/00077 0		2/6/2009
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER		US		12/866,702		11/11/2010
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER		AU		2009210654		2/6/2009
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER		CA		2,715,348		2/6/2009
USE OF PICOPLATIN AND 13EVACIZUMAB TO TREAT COLORECTAL CANCER		UN		200980109758.6		2/6/2009
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER		EP		09708527.8		2/6/2009
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER		HK		11109428.0		2/6/2009
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER		JP		2010-545883		2/6/2009

 

 

Patent		Country		Application No. or Registration No. (as applicable)		Application Filing Date or Registration Date (as applicable)
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER		US		61/027,382		2/8/2008
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER		PCT		PCT/US2009/00077 3		2/6/2009
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER		US		12/866,706		11/15/2010
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER		AU		2009210656		2/6/2009
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER		CA		2,715,353		2/6/2009
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER		CN		200980111015.2		2/6/2009
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER		EP		097083873		2/6/2009
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER		HK		111094253		2/6/2009
USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER		JP		2010-545885		2/6/2009
USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER		US		61/027,360		2/8/2008

 

 

				Application No.
				or Registration		Application Filing
				No.		Date or Registration
Patent		Country		(as applicable)		Date (as applicable)
PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER		PCT		PCT/US2009/00075 0		2/6/2009
PICOPLAT1N AND AMRUBICIN TO TREAT LUNG CANCER		US		12/866,710		11/10/2010
PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER		AU		2009210734		2/6/2009
PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER		CA		2,715,329		2/6/2009
PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER		CN		200980110139.9		2/6/2009
PICOPLAT1N AND AMRUBICIN TO TREAT LUNG CANCER		EP		09708292.9		2/6/2009
PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER		HK		11109534J		2/6/2009
PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER		JP		2010-545878		2/6/2009
COMBINATION CHEMOTHERAPY COMPRISING STABILIZED INTRAVENOUS PICOPLATIN DOSAGE FORM		US		61/027,388		2/8/2008
COMBINATION CHEMOTHERAPY COMPRISING STABILIZED INTRAVENOUS PICOPLATIN DOSAGE FORM		US		61/055/071		5/21/2008

 

 

Patent		Country		Application No. or Registration No. (as applicable)		Application Filing Date or Registration Date (as applicable)
STABILIZED PICOPLATIN DOSAGE FORM		PCT		PCT/U52008/08076		6/27/2008
STABILIZED PICOPLATIN DOSAGE FORM		US		12/635,517		12/10/2009
COMBINATION THERAPY FOR OVARIAN CANCER		US		12/635,534		12/10/2009
COMBINATION THERAPY FOR OVARIAN CANCER		US		12/781,599		5/17/2010
COMBINATION THERAPY FOR OVARIAN CANCER		PCT		PCT/US11/036855		5/17/2011
STABILIZED PICOPLATIN DOSAGE FORM		AU		2008295576		6/27/2008
STABILIZED PICOPLATIN DOSAGE FORM		BR		P10811816-7		6/27/2008
STABILIZED PICOPLATIN DOSAGE FORM		CA		2,691,115		6/27/2008
STABILIZED PICOPLATIN DOSAGE FORM		CN		200880022248.0		6/27/2008
STABILIZED PICOPLATIN DOSAGE FORM		EP		08828991.3		6/27/2008
STABILIZED PICOPLATIN DOSAGE FORM		HK		10108170.3		6/27/2008

 

 

				Application No. or Registration No.		Application Filing Date or Registration
Patent		Country		(as applicable)		Date (as applicable)
STABILIZED PICOPLATIN DOSAGE FORM		ID		W-00201000277		6/27/2008
STABILIZED PICOPLATIN DOSAGE FORM		ru				6/27/208
STABILIZED PICOPLATIN DOSAGE FORM		IN		7725/CHENP/2009		6/27/2008
STABILIZED PICOPLATIN DOSAGE FORM		JP		20 10-5 14837		6/27/2008
STABILIZED PICOPLATIN DOSAGE FORM		KR		10-2010-7001745		6/27/2008
STABILIZED PICOPLATIN DOSAGE FORM		MX		MX/a12009/013835		6/27/2008
STABILIZED PICOPLATIN DOSAGE FORM		RU		2010102096		6/27/2008
STABILIZED PICOPLATIN DOSAGE FORM		TW		097124033		6/28/2008
STABILIZED PICOPLATIN DOSAGE FORM		UA		201000817		6/28/2008
PICOPLATIN ORAL DOSAGE FORM HAVING HIGH BIOAVAILABILITY		US		61/169,679		4/15/2009
PICOPLATIN ORAL DOSAGE FORM HAVING HIGH BIOAVAILABILITY		US		61/170,487		4/17/2009
HIGH BIOVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY		PCT		PCT/U52010/00735		3/11/2010

 

 

				Application No.
				or Registration		Application Filing
				No.		Date or Registration
Patent		Country		(as applicable)		Date (as applicable)
HIGH BIOVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY		US		13/264,343		10/13/2011
USE OF PICOPLATIN TO TREAT PROSTATE CANCER		US		61/177,567		5/12/2009
USE OF PICOPLATIN TO TREAT PROSTATE CANCER		PCT		PCT/U52010/34591		5/12/2010
USE OF PICOPLATIN TO TREAT PROSTATE CANCER		US		13/319,647		11/9/2011
USE OF PICOPLATING AND DOCETAXEL TO TREAT PROSTATE CANCER		US		61/177,571		5/12/2009
IMPROVED SYNTHESIS OF PICOPLATIN		US		61/186,526		6/12/2009
IMPROVED SYNTHESIS OF PICOPLATIN		PCT		PCT/US2010/38348		6/11/2010
IMPROVED SYNTHESIS OF PICOPLATIN		TW		099119171		6/11/2010
METHOD TO TREAT SMALL CELL LUNG CANCER		US		61/311,169		3/5/2010
METHOD TO TREAT SMALL CELL LUNG CANCER		US		61/345,442		5/17/2010
METHOD TO TREAT SMALL CELL LUNG CANCER		PCT		PCT/U52011/02726 4		3/4/2011

 

 

Patent		Country		Application No. or Registration No, (as applicable)		Application Filing Date or Registration Date (as applicable)
METHOD TO TREAT SMALL CELL LUNG CANCER		TW		100 1076 12		3/7/2011
COMBINATION THERAPY FOR SMALL CELL LUNG CANCER		US		61/345,451		5/17/2010
COMBINATION THERAPY FOR SMALL CELL LUNG CANCER		US		61/346,777		5/20/2010
COMBINATION THERAPY FOR SMALL CELL LUNG CANCER		PCT		PCT/1J52011/02726		3/4/2011
COMBINATION THERAPY FOR SMALL CELL LUNG CANCER		TW		100107621		3/7/2011
INHIBITORS OF FOCAL ADHESION KINASE		PCT		PCT/1J52008/00320		3110/2008
INHIBITORS OF FOCAL ADHESION KINASE		US		12/531,010		9/11/2009
INHIBITORS OF FOCAL ADHESION KINASE		CA		2,681,015		3/10/2008
INHIBITORS OF FOCAL ADHESION KINASE		CN		200880015910.X		3/10/2008
INHIBITORS OF FOCAL ADHESION KINASE		EP		08726698.7		3/10/2008
INHIBITORS OF FOCAL ADHESION KINASE		HK		10107956.5		3/10/2008
INHIBITORS OF FOCAL ADHESION KINASE		IN		5948/DELNP/2009		3/10/2008
INHIBITORS OF FOCAL ADHESION KINASE		JP		2009-553600		3/10/2008
INHIBITORS OF FOCAL ADHESION KINASE		TW		97109125		3/14/2008

 

 

Patent		Country		Application No. or Registration No. (as applicable)		Application Filing Date or Registration Date (as applicable)
METHODS OF PROMOTING APOPTOSIS AND INHIBITING METASTASIS		PCT		PCT/US2010/04535		8/12/2010
SYNTHESIS AND USE OF KINASE INHIBITORS		US		61/359,942		6/30/2010
SYNTHESIS AND USE OF KINASE INHIBITORS		PCT		PCT/US2011/04216		6/28/2011
ORAL FORMULATION OF 1UNASE INHIBITORS		US		61/359,694		6/29/2010
ORAL FORMULATION OF KINASE INHIBITORS		PCT		PCT/U52011/04216		6/28/2011